SLC5A2 and chronic kidney disease: Based on the results of EMPA-KIDNEY trial, the SGLT2 inhibitor empagliflozin was also FDA approved a new indication for the treatment of adults with chronic kidney disease (CKD) regardless of diabetes diagnosis [4,5].